The assessment and diagnostic workup of newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) is evolving, as discussed here by Nathan Pennell, MD, PhD, of the Cleveland Clinic, Cleveland, OH. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Prof. Pennell highlights the need for enough biopsy material to perform the array of biomarker tests now available, as well as the need for speed during this process.
Assessment and diagnostic workup for NSCLC in 2018
